Technetium Tc-99M Sestamibi
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Technetium Tc-99M Sestamibi
- Technetium Tc-99m Sestamibi: From Diagnostic Imaging to Homozygous Familial Hypercholesterolemia
Technetium Tc-99m Sestamibi: From Diagnostic Imaging to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Technetium Tc-99m Sestamibi is a radioactive diagnostic imaging agent, marketed in the US as a kit for injection. Its listed uses in the source material are perfusion and parathyroid imaging. The TxGNN model predicts it may be relevant to homozygous familial hypercholesterolemia (HoFH), but only 1 publication (a case report) and 0 clinical trials support this, so the prediction is not backed by clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the US license records; diagnostic imaging agent (myocardial perfusion / parathyroid imaging) |
| Predicted New Indication | Homozygous familial hypercholesterolemia |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 (all listed as ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sestamibi is a diagnostic radiopharmaceutical rather than a therapeutic drug. It is used to image tissue, not to treat disease.
The only supporting record is a 2015 case report. In a patient whose HoFH diagnosis was delayed, Tc-99m MIBI myocardial perfusion imaging was used alongside 18F-FDG PET to assess cardiac involvement. This is incidental diagnostic use for cardiovascular complications of HoFH, not a disease-specific mechanism.
The very high TxGNN score is therefore not supported by clinical evidence. Scores across all of this drug’s predicted indications are saturated near 0.997–0.999, so they do not discriminate well between candidates.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26298359 | 2015 | Case report | Int J Cardiol | 18F-FDG PET and Tc-99m MIBI myocardial perfusion imaging used in a patient with delayed diagnosis of HoFH (summarized from the title; no abstract available) |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA079157 | Kit for the Preparation of Technetium Tc99m Sestamibi (Sun Pharmaceutical Industries) | Injection | Not specified in source data |
| ANDA078809 | Kit for the Preparation of Technetium Tc99m Sestamibi (Cardinal Health 414) | Injection, powder, lyophilized, for solution | Not specified in source data |
| ANDA078806 | Technetium Tc 99m Sestamibi (Jubilant Draximage) | Injection, powder, for solution | Not specified in source data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only evidence for HoFH is a single case report of incidental diagnostic use. There are no registered trials and no plausible disease-specific mechanism, so the high model score is not clinically supported.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data and the approved indication text
- Any prospective study showing a diagnostic role specific to HoFH
For context, other predictions for this drug have more support. Multiple endocrine neoplasia (parathyroid localization) has cohort studies and case reports (L3) and is rated “Proceed with Guardrails”. That use would be diagnostic only, as adjunctive pre-operative localization.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.